Stock Name | Peer Group Rank | RS Rating | 1 Month RS | 3 Month RS | Listing Date | Basic Industry | Market Cap(Cr.) | 1 Day Returns(%) | 1 Week Returns(%) | 1 Month Returns(%) | 3 Month Returns(%) | 6 Month Returns(%) | 1 Year Returns(%) | % from 52W High | % from 52W Low | Chart Type | Stock Price(₹) | 200 Days MA | 150 Days MA | 50 Days MA | 20 Days MA | 200 Days EMA | 50 Days EMA | 21 Days EMA | 20 Days EMA | 10 Days EMA | 30 Days Average Rupee Volume(Cr.) | 1 Month High | 3 Month High | Float Shares(Cr.) | Index | 52 Week High | Volume Spike | Gap Up | Dense Volume | Sector | Free Float(%) | Is HVE | HVE Date | Is Positive Volume HVE | Is HVY | HVY Date | Is Positive Volume HVY | Is HVQ | HVQ Date | Is Positive Volume HVQ | Day Range(%) | Is F&O Stock | Circuit Limit | RVOL | Daily Rupee Turnover 20(Cr.) | Daily Rupee Turnover 50(Cr.) | Daily Rupee Turnover 100(Cr.) | Is NR7 | 20 Days MA Volume | 50 Days MA Volume | 200 Days EMA Volume | 50 Days EMA Volume | 20 Days EMA Volume | Trend Reversal | % from 52W High 200 Days EMA Volume | 200 Days EMA RS | 50 Days EMA RS | 20 Days EMA RS | % from 52W High RS | 5 Days MA ADR(%) | 14 Days MA ADR(%) | 20 Days MA ADR(%) | 30 Days MA ADR(%) | % Days in 125: EMA50 today > yesterday | % Days in 125: Today's price > EMA50 | % from ATH | Quarterly Results Date | Gap Up % | MA Uptrend | FVG | Backtesting Closing Data | Highest Close Since Last Quarter | Past Result Dates | Company Name | Returns since Earnings(%) | Max Returns since Earnings(%) | Latest Investor Presentation Link | 3 Day Range(%) | 5 Day Range(%) | 7 Day Range(%) | 20 Day Range(%) | Horizontal Resistance Line Data | Tight Zone Data | Inside Bar Dates | VCP Drawings Data | Net Profit Latest Quarter | Net Profit Previous Quarter | Net Profit 2 Quarters Back | Net Profit 3 Quarters Back | Net Profit Last Year Quarter | Net Profit 5 Quarters Back | Net Profit 6 Quarters Back | Net Profit 7 Quarters Back | QoQ % Net Profit Latest | YoY % Net Profit Latest | EPS Latest Quarter | EPS Previous Quarter | EPS 2 Quarters Back | EPS 3 Quarters Back | EPS Last Year Quarter | EPS 5 Quarters Back | EPS 6 Quarters Back | EPS 7 Quarters Back | QoQ % EPS Latest | YoY % EPS Latest | EPS Last Year | EPS 2 Years Back | Sales Latest Quarter | Sales Previous Quarter | Sales 2 Quarters Back | Sales 3 Quarters Back | Sales Last Year Quarter | Sales 5 Quarters Back | Sales 6 Quarters Back | Sales 7 Quarters Back | QoQ % Sales Latest | YoY % Sales Latest | Sales Growth 5 Years(%) | OPM Latest Quarter | OPM Previous Quarter | OPM 2 Quarters Back | OPM 3 Quarters Back | OPM Last Year Quarter | OPM 5 Quarters Back | OPM 6 Quarters Back | OPM 7 Quarters Back | QoQ % OPM Latest | YoY % OPM Latest | Latest Quarter | ROE(%) | ROCE(%) | D/E | OPM TTM(%) | P/E | FII % change QoQ | DII % change QoQ | Promoter % change QoQ | PEG | Forward P/E | Historical P/E 5 Years | Company Info | Promotor Holding Latest Quarter(%) | Public Holding Latest Quarter(%) | FII Holding Latest Quarter(%) | DII Holding Latest Quarter(%) | Promotor Holding Previous Quarter(%) | FII Holding Previous Quarter(%) | DII Holding Previous Quarter(%) | Price to Book | Enterprise Value(Cr.) | Enterprise Value/EBITDA | Enterprise Value/Sales |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2 | 79 | 98 | 88 | 24/10/2003 | Healthcare Research Analytics & Technology | 4693 | 5.3 | 12.7 | 31 | 11.5 | -12.7 | 49.1 | 40.7 | 50.4 | DAILY | 177.98 | 193.75 | 173.22 | 145.8 | 143.92 | 168.97 | 149.22 | 149.51 | 149.84 | 157.17 | 9.2 | True | True | 7.87 | NA | False | False | False | 89.7 | Healthcare | 29.8 | False | False | False | False | False | False | 8.5 | False | 20 | 1.14 | 3.6 | 2.6 | 1.9 | False | 630040.2 | 455991.46 | 389989.01 | 498084.99 | 656511.38 | False | 51.7 | 81.34 | 77.92 | 77.54 | 14.1 | 8.3 | 6.8 | 6.1 | 5.5 | 8 | 8 | 40.7 | NA | 0.6 | False,False;False,False;False,False | [False, False, False] | ['2025-07-15', 300.0, '2025-04-09', 118.3] | 177.98 | Dec 2025:29/01/2026,Sep 2025:11/11/2025,Jun 2025:13/08/2025 | Suven Life Sciences Limited | 35.6 | 39 | Jun 2025:NA | 10.1 | 23.1 | 28.8 | 32 | [180.2, '21/11/2025', 'DAILY'][180.2, '15/12/2025', 'WEEKLY'] | -101.92 | -77.31 | -51.52 | -43.94 | -39.12 | -49.64 | -28.04 | -26.54 | -31.8 | -160.5 | -4.48 | -3.4 | -2.36 | -2.01 | -1.79 | -2.28 | -1.29 | -1.22 | -31.8 | -150.3 | -7.37 | -4.82 | 2.81 | 0.92 | 1.87 | 1.47 | 1.61 | 2.57 | 1.01 | 2.39 | 205.4 | 74.5 | -12 | -3677.94 | -8670.65 | -2713.9 | -2980.95 | -2434.78 | -2031.52 | -3023.76 | -1266.95 | 57.6 | -51.1 | Dec 2025 | -87.22 | -86.96 | 0 | -3927.72 | -14.5 | -0.35 | 1.23 | 2.79 | NA | -9.93 | NA | Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. The company engages in drug discovery and development of new chemical entities in central nervous system diseases. Its product candidates include Masupirdine (SUVN-502) for the treatment of Alzheimer disease and neuropsychiatric symptoms; Samelisant (SUVN-G3031), a histamine 3 receptor inverse agonist for the treatment of sleep and cognitive disorders; and Ropanicant (SUVN-911), Alpha4Beta2 nAChRs receptor antagonist for the treatment of depressive disorders. The company is developing Usmarapride (SUVN-D4010), a potent, selective, and orally bio-available and brain penetrant 5-HT4 receptor partial agonist for the treatment of cognitive disorders; SUVN-I6107 for the treatment of cognitive disorders; SUVN-M8036 for the treatment of psychiatric disorders; and SUVN-D1044 for the treatment of gastrointestinal disorders. The company was formerly known as Suven Pharmaceuticals Pvt. Ltd. and changed its name to Suven Life Sciences Limited in 2003. The company was incorporated in 1989 and is headquartered in Hyderabad, India. Suven Life Sciences Limited is a subsidiary of Jasti Property and Equity Holdings Private Limited. **Website:** [https://www.suven.com](https://www.suven.com) | 70.15 | 24.42 | 0.82 | 4.62 | 67.36 | 1.17 | 3.39 | 14.39 | 4683.19 | -17.39 | 662.4 | |||||||
| 1 | 99 | 95 | 80 | 27/08/2007 | Healthcare Research Analytics & Technology | 659 | 2 | 8.2 | 23.7 | 4.6 | 190.1 | 446.4 | 10.7 | 510.8 | DAILY | 44.59 | 25.98 | 31.34 | 41.9 | 40.02 | 30.21 | 40.47 | 40.93 | 40.94 | 41.67 | 2.2 | False | False | 14.79 | NA | False | False | False | 109.7 | Healthcare | 100 | False | False | False | False | False | False | 0 | False | 2 | 2.1 | 2.5 | 3.9 | 6.8 | False | 541265.3 | 852530.66 | 911806.78 | 832704.15 | 654092.94 | False | 12 | 98.61 | 99 | 99 | 0 | 0 | 0 | 1.1 | 2 | 86.4 | 86.4 | 85.5 | NA | 2 | True,True;True,True;True,True | [True, False, False] | ['2026-02-13', 49.9, '2025-05-09', 7.3] | 47.49 | Dec 2025:14/02/2026,Sep 2025:27/10/2025,Jun 2025:07/07/2025 | Take Solutions Limited | -8.7 | 0.4 | Jun 2025:NA | 3.9 | 7.6 | 11.1 | 19.1 | 1.11 | 6.29 | -0.91 | -4.88 | 47.68 | -1.58 | -3.75 | -110.61 | -82.4 | -97.7 | 0.08 | 0.43 | -0.06 | -0.33 | 3.22 | -0.11 | -0.25 | -7.48 | -81.4 | -97.5 | 2.53 | -8.09 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | Dec 2025 | 644.12 | 11.24 | 0 | NA | 405.4 | 0.56 | 0 | -5.19 | 122.2 | 139.34 | 122.21 | TAKE Solutions Limited, together with its subsidiaries, provides domain-intensive services in life sciences and software and information technology in India. The company offers clinical research, generics development, data sciences, regulatory affairs, and pharmacovigilance and safety services backed by technology expertise. It also provides embed digital and employ mobile solutions for patient centricity insight in life science sector; and payer solutions, including access to billing insight through cloud adoption. In addition, the company offers payer-provider digital solution, which includes personalized medicine, wellness, and patient engagement; and medical device solution, such as technological transformation with chip level programming, wearables, DICOM devices, PROM, nano devices, and miOTs. TAKE Solutions Limited was incorporated in 2000 and is headquartered in Chennai, India. TAKE Solutions Limited is a subsidiary of TAKE Solutions Pte. Limited. **Website:** [https://www.takesolutions.com](https://www.takesolutions.com) | 0 | 99.44 | 0.56 | 0 | 5.19 | 0 | 0 | 25.74 | 659.49 | 686.97 | NA | ||||||||
| 3 | 55 | 73 | 62 | 13/05/2024 | Healthcare Research Analytics & Technology | 11809 | 1.5 | 3.7 | 8.4 | -3.9 | -11.4 | -11.4 | 22.5 | 18.4 | DAILY | 490.25 | 527.32 | 513.57 | 469.48 | 452.06 | 516.97 | 471.27 | 462.45 | 462.45 | 467.34 | 20.1 | True | False | 24.09 | Nifty 500,Nifty Smallcap 250,Nifty Midsmallcap 400 | False | False | False | 80.4 | Healthcare | 100 | False | False | False | False | False | False | 4.9 | False | 20 | 0.56 | 26.2 | 25.5 | 18.7 | False | 447436 | 434757 | 773349.28 | 413780.62 | 444247.57 | False | 82.4 | 53.5 | 54.42 | 54.47 | 8.3 | 4.2 | 4.3 | 3.9 | 3.7 | 5.6 | 5.6 | 33.4 | NA | -0.1 | False,False;False,False;False,False | [False, False, False] | ['2025-06-03', 632.9, '2026-03-23', 414.0] | 500.3 | Dec 2025:29/01/2026,Sep 2025:30/10/2025 | Indegene Limited | 4.5 | 9 | Jun 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=068c1e0a-442b-4d68-930d-b0dce69857b6.pdf,Sep 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=39946df0-2acb-4227-b535-273b388588ad.pdf,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/abed814d-2aef-453f-bae5-121602424a52.pdf | 6.5 | 9.1 | 12.2 | 16 | [507.9, '03/02/2026', 'DAILY'] | 102.9 | 102.1 | 116.4 | 117.6 | 109.7 | 91.7 | 87.7 | 94.8 | 0.8 | -6.2 | 4.28 | 4.25 | 4.85 | 4.9 | 4.58 | 3.83 | 3.67 | 4.26 | 0.7 | -6.6 | 16.95 | 15.14 | 942.1 | 804.2 | 760.8 | 755.6 | 720.4 | 686.8 | 676.5 | 673 | 17.1 | 30.8 | 34.59 | 16.93 | 17.48 | 20.41 | 19.52 | 18.3 | 18.36 | 19.05 | 20.61 | -3.1 | -7.5 | Dec 2025 | 20.59 | 24.8 | 0.04 | 18.48 | 26.8 | 0.18 | 1.11 | 0 | 0.91 | 28.64 | 33.95 | Indegene Limited operates as a digital-first life sciences commercialization company in India, the United States, Europe, and internationally. It operates through three segments: Enterprise Medical Solutions, Enterprise Commercial Solutions, Omnichannel Activation & Others. The company develops biotech and medical device for biopharmaceutical, emerging biotech, and medical device companies. It also offers enterprise commercial, medical, and clinical solutions; and omnichannel activation solutions. In addition, the company operates NEXT technology platforms. Further, it provides analytics, technology, commercial, medical, regulatory, and safety services to life science and healthcare organizations. Indegene Limited was incorporated in 1998 and is based in Bengaluru, India. **Website:** [https://www.indegene.com](https://www.indegene.com) | 0 | 80.44 | 11.48 | 8.06 | 0 | 11.3 | 6.95 | 4.11 | 11445.77 | 16.6 | 3.51 | |||||||
| 4 | 33 | 39 | 10 | 15/12/2005 | Healthcare Research Analytics & Technology | 1956 | -1.3 | 7.1 | 1.2 | -24.2 | -39.3 | 2.7 | 51.5 | 16.5 | DAILY | 437.95 | 581.78 | 588.53 | 441.53 | 420.32 | 527.93 | 454.74 | 425.31 | 424.65 | 421.95 | 7.4 | False | False | 2.86 | NA | False | False | False | 19.9 | Healthcare | 64.1 | False | False | False | False | False | False | 4.6 | False | 20 | 0.85 | 7.5 | 11 | 8.2 | False | 177546.7 | 261855.52 | 666820.85 | 223091.33 | 193924.62 | False | 63.8 | 51.4 | 29.92 | 27.05 | 63.7 | 4.8 | 4.9 | 4.6 | 4.3 | 6.4 | 6.4 | 51.5 | NA | 0.3 | False,False;False,False;False,False | [True, False, False] | ['2025-09-05', 902.7, '2026-03-30', 376.0] | 495.9 | Dec 2025:28/01/2026,Sep 2025:03/11/2025,Jun 2025:17/07/2025 | Vimta Labs Limited | -4.1 | 13.7 | Jun 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a58210b2-ea70-455f-bb6f-58046d9da442.pdf,Sep 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=282156ae-d831-4232-a288-bfca08e9e180.pdf,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/d6d80f3e-9a8e-4e31-86e9-8ff50b19cad3.pdf | 10.5 | 13.7 | 17.2 | 18.3 | 17.59 | 19.92 | 18.89 | 18.32 | 21.5 | 15.25 | 12.28 | 12.35 | -11.7 | -18.2 | 3.94 | 4.47 | 4.24 | 4.12 | 4.84 | 3.44 | 2.77 | 2.79 | -11.9 | -18.6 | 15.13 | 9.26 | 98.63 | 101.85 | 97.56 | 94.44 | 89.92 | 84.74 | 74.88 | 72.73 | -3.2 | 9.7 | 13.74 | 34.72 | 33.6 | 34.53 | 34.99 | 36.78 | 35.3 | 34.62 | 35.64 | 3.3 | -5.6 | Dec 2025 | 19.43 | 25.22 | 0.02 | 34.45 | 26.1 | 0.26 | -0.76 | -0.09 | 1.51 | 27.79 | 24.4 | Vimta Labs Limited provides contract research and testing services in India and internationally. The company offers drug discovery, development, and drug life cycle management support services in the areas of preclinical research, clinical research, and analytical services for biopharmaceutical companies; preclinical research and testing services for medical device companies; and contract research and testing for agrochemical and specialty chemical companies. It also provides food testing and analytical development services to support manufacturers, processors, farmers, retailers, traders, exporters, and regulators; and a testing laboratory for water, alcoholic, and non-alcoholic beverages. In addition, the company offers environmental regulatory services, such as impact assessments and post project monitoring, to various industries, including power, infrastructure, cement, oil and gas, and mining, etc.; and EMI/EMC testing for electronic and electrical products/components. It provides solutions to agriculture, biologics and biosimilars, home and personal care, medical device, specialty chemicals, food, electrical and electronics, nutraceuticals, water and beverages, pharmaceuticals, crop care, environment, health and safety, and packaging industries. Vimta Labs Limited was founded in 1984 and is headquartered in Hyderabad, India. **Website:** [https://vimta.com](https://vimta.com) | 35.9 | 59.4 | 4.59 | 0.11 | 35.99 | 4.33 | 0.87 | 4.69 | 1907.01 | 13.33 | 4.86 | ||||||||
| 5 | 3 | 27 | 1 | 11/08/2015 | Healthcare Research Analytics & Technology | 15839 | -1.5 | 0.5 | -1.4 | -37.3 | -38.4 | -43.2 | 47.9 | 3.4 | DAILY | 393.1 | 592.91 | 570.62 | 428.22 | 404.85 | 569.57 | 444.85 | 406.69 | 405.76 | 398.63 | 72.5 | False | False | 19.07 | Nifty Healthcare,Nifty 500,Nifty Smallcap 250,Nifty Midsmallcap 400 | False | False | False | 140.6 | Healthcare | 47.3 | False | False | False | False | True | 13/03/2026 | True | 3.7 | False | 20 | 0.53 | 113.1 | 99.8 | 69.9 | False | 1769880.15 | 1551330.1 | 1092753.34 | 1447145.22 | 1565635.45 | False | 2.3 | 7.6 | 4.67 | 3.68 | 78.6 | 3.4 | 3.8 | 3.7 | 3.3 | 26.4 | 26.4 | 59.1 | NA | 0.8 | False,False;False,False;False,False | [False, False, False] | ['2025-04-23', 754.8, '2026-04-06', 380.0] | 592.6 | Dec 2025:22/01/2026,Sep 2025:05/11/2025,Jun 2025:23/07/2025 | Syngene International Limited | -33.7 | 2.8 | Jun 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b5e36714-6bb1-40e5-9d19-71fb01eee0c8.pdf,Sep 2025:https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=47df660d-9183-4cf3-b1a3-a77644a0c641.pdf,Dec 2025:https://www.bseindia.com/xml-data/corpfiling/AttachLive/53091019-7daa-44d0-bc7d-fd03b4c2899e.pdf | 3.8 | 6.3 | 7.3 | 11.2 | ['WEEKLY', '2026-04-06', '2026-03-30'] | 15 | 67.1 | 86.7 | 183.3 | 131.1 | 106.1 | 75.7 | 188.6 | -77.6 | -88.6 | 0.37 | 1.67 | 2.15 | 4.55 | 3.26 | 2.64 | 1.88 | 4.69 | -77.8 | -88.7 | 12.33 | 12.69 | 917.1 | 910.6 | 874.5 | 1018 | 943.7 | 891 | 789.7 | 916.9 | 0.7 | -2.8 | 12.6 | 22.81 | 21.91 | 23.6 | 33.75 | 30.05 | 27.47 | 21.5 | 34.56 | 4.1 | -24.1 | Dec 2025 | 10.53 | 13.52 | 0.12 | 25.77 | 45 | -1.35 | 1.21 | 0 | 9.1 | 265.61 | 57.21 | Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals; and chemical, formulation, analytical, and clinical development services, as well as commercial manufacturing and sterile fill-finish services. It also provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical studies, biometrics and clinical data management, central lab, regulatory, medical monitoring, pharmacovigilance, and medical writing services. In addition, the company offers chemistry, biology, safety assessment, computational, and data sciences for traditional small molecule therapeutics; biologics; and specialty modalities, such as peptides, oligonucleotides, antibody-drug conjugates, and targeted degradation/stabilization. It serves pharmaceutical, biotechnology, animal health, nutrition, consumer goods, agrochemical, performance and specialty materials, and other companies. The company has collaborations with Bristol-Myers Squibb, Baxter Inc., and Amgen Inc. The company was incorporated in 1993 and is headquartered in Bengaluru, India. Syngene International Limited is a subsidiary of Biocon Limited. **Website:** [https://www.syngeneintl.com](https://www.syngeneintl.com) | 52.68 | 6.22 | 14.96 | 25.83 | 52.68 | 16.31 | 24.62 | 3.35 | 15837.18 | 15.43 | 4.26 |
Quarter | EPS | QoQ EPS | YoY EPS | Sales(Cr.) | QoQ Sales | YoY Sales | OPM |
|---|---|---|---|---|---|---|---|
Dec 25 | -4.48 | -31.8 | -150.3 | 2 | 205.4 | 74.5 | -3677.94 |
Sep 25 | -3.4 | -44.1 | -49.1 | 0 | -50.8 | -64.2 | -8670.65 |
Jun 25 | -2.36 | -17.4 | -82.9 | 1 | 27.2 | 85.1 | -2713.9 |
Mar 25 | -2.01 | -12.3 | -64.8 | 1 | -8.7 | -38.5 | -2980.95 |
Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. The company engages in drug discovery and development of new chemical entities in central nervous system diseases. Its product candidates include Masupirdine (SUVN-502) for the treatment of Alzheimer disease and neuropsychiatric symptoms; Samelisant (SUVN-G3031), a histamine 3 receptor inverse agonist for the treatment of sleep and cognitive disorders; and Ropanicant (SUVN-911), Alpha4Beta2 nAChRs receptor antagonist for the treatment of depressive disorders. The company is developing Usmarapride (SUVN-D4010), a potent, selective, and orally bio-available and brain penetrant 5-HT4 receptor partial agonist for the treatment of cognitive disorders; SUVN-I6107 for the treatment of cognitive disorders; SUVN-M8036 for the treatment of psychiatric disorders; and SUVN-D1044 for the treatment of gastrointestinal disorders. The company was formerly known as Suven Pharmaceuticals Pvt. Ltd. and changed its name to Suven Life Sciences Limited in 2003. The company was incorporated in 1989 and is headquartered in Hyderabad, India. Suven Life Sciences Limited is a subsidiary of Jasti Property and Equity Holdings Private Limited.
Website: https://www.suven.com
Disclaimer: This stock summary is generated by AI. ChartsMaze does not guarantee its accuracy, completeness, or timeliness. The data may be outdated and may not reflect real-time events or news. Please verify the information independently before making any investment decisions. For more details, check our Terms & Conditions.